KRAS and non-small cell lung carcinoma: siRNA knockdown of mutant KRAS was associated with a substantial reduction in cytoplasmic EZH2 in A549 cells, an increase in DLC1 protein in A549 and four other NSCLC lines with mutant KRAS, and two lines with wild-type KRAS.